MOLECULAR PARTNERS AG -ADR (MOLN) Stock Fundamental Analysis

NASDAQ:MOLN • US60853G1067

4.605 USD
-0.04 (-0.97%)
Last: Feb 13, 2026, 08:26 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall MOLN gets a fundamental rating of 2 out of 10. We evaluated MOLN against 523 industry peers in the Biotechnology industry. While MOLN seems to be doing ok healthwise, there are quite some concerns on its profitability. MOLN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year MOLN has reported negative net income.
  • MOLN had a negative operating cash flow in the past year.
  • In the past 5 years MOLN reported 4 times negative net income.
  • In the past 5 years MOLN reported 4 times negative operating cash flow.
MOLN Yearly Net Income VS EBIT VS OCF VS FCFMOLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

  • MOLN has a Return On Assets of -48.19%. This is comparable to the rest of the industry: MOLN outperforms 52.58% of its industry peers.
  • Looking at the Return On Equity, with a value of -56.57%, MOLN is in the better half of the industry, outperforming 63.86% of the companies in the same industry.
Industry RankSector Rank
ROA -48.19%
ROE -56.57%
ROIC N/A
ROA(3y)-6.8%
ROA(5y)-18.16%
ROE(3y)-7.72%
ROE(5y)-28.23%
ROIC(3y)N/A
ROIC(5y)N/A
MOLN Yearly ROA, ROE, ROICMOLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

  • Looking at the Gross Margin, with a value of 99.80%, MOLN belongs to the top of the industry, outperforming 99.04% of the companies in the same industry.
  • MOLN's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for MOLN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.14%
GM growth 5Y0.01%
MOLN Yearly Profit, Operating, Gross MarginsMOLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • MOLN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MOLN has more shares outstanding
  • Compared to 5 years ago, MOLN has more shares outstanding
  • The debt/assets ratio for MOLN has been reduced compared to a year ago.
MOLN Yearly Shares OutstandingMOLN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
MOLN Yearly Total Debt VS Total AssetsMOLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • MOLN has an Altman-Z score of 0.43. This is a bad value and indicates that MOLN is not financially healthy and even has some risk of bankruptcy.
  • With a decent Altman-Z score value of 0.43, MOLN is doing good in the industry, outperforming 62.33% of the companies in the same industry.
  • MOLN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.00, MOLN perfoms like the industry average, outperforming 48.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.43
ROIC/WACCN/A
WACC4.89%
MOLN Yearly LT Debt VS Equity VS FCFMOLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • MOLN has a Current Ratio of 9.28. This indicates that MOLN is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of MOLN (9.28) is better than 79.73% of its industry peers.
  • MOLN has a Quick Ratio of 9.28. This indicates that MOLN is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of MOLN (9.28) is better than 79.73% of its industry peers.
Industry RankSector Rank
Current Ratio 9.28
Quick Ratio 9.28
MOLN Yearly Current Assets VS Current LiabilitesMOLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • MOLN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.05%, which is quite good.
  • MOLN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -29.38%.
  • Measured over the past years, MOLN shows a very negative growth in Revenue. The Revenue has been decreasing by -24.59% on average per year.
EPS 1Y (TTM)16.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.65%
Revenue 1Y (TTM)-29.38%
Revenue growth 3Y-20.13%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, MOLN will show a decrease in Earnings Per Share. The EPS will decrease by -3.81% on average per year.
  • The Revenue is expected to grow by 96.98% on average over the next years. This is a very strong growth
EPS Next Y6.91%
EPS Next 2Y4.57%
EPS Next 3Y19.94%
EPS Next 5Y-3.81%
Revenue Next Year-83.33%
Revenue Next 2Y35.4%
Revenue Next 3Y108.01%
Revenue Next 5Y96.98%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MOLN Yearly Revenue VS EstimatesMOLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
MOLN Yearly EPS VS EstimatesMOLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • MOLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MOLN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MOLN Price Earnings VS Forward Price EarningsMOLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MOLN Per share dataMOLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MOLN's earnings are expected to grow with 19.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.57%
EPS Next 3Y19.94%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • MOLN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MOLECULAR PARTNERS AG -ADR

NASDAQ:MOLN (2/13/2026, 8:26:48 PM)

4.605

-0.04 (-0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-25
Earnings (Next)03-12
Inst Owners43.98%
Inst Owner Change-0.14%
Ins Owners4%
Ins Owner ChangeN/A
Market Cap172.22M
Revenue(TTM)4.97M
Net Income(TTM)-54.04M
Analysts82
Price Target12.26 (166.23%)
Short Float %0.05%
Short Ratio3.39
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.81%
PT rev (3m)-11.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-33.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 26.68
P/FCF N/A
P/OCF N/A
P/B 1.39
P/tB 1.39
EV/EBITDA N/A
EPS(TTM)-1.98
EYN/A
EPS(NY)-1.89
Fwd EYN/A
FCF(TTM)-1.88
FCFYN/A
OCF(TTM)-1.85
OCFYN/A
SpS0.17
BVpS3.32
TBVpS3.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.19%
ROE -56.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.8%
FCFM N/A
ROA(3y)-6.8%
ROA(5y)-18.16%
ROE(3y)-7.72%
ROE(5y)-28.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.14%
GM growth 5Y0.01%
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.33%
Cap/Sales 14.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.28
Quick Ratio 9.28
Altman-Z 0.43
F-Score3
WACC4.89%
ROIC/WACCN/A
Cap/Depr(3y)41.08%
Cap/Depr(5y)46.5%
Cap/Sales(3y)8.93%
Cap/Sales(5y)11.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.65%
EPS Next Y6.91%
EPS Next 2Y4.57%
EPS Next 3Y19.94%
EPS Next 5Y-3.81%
Revenue 1Y (TTM)-29.38%
Revenue growth 3Y-20.13%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%
Revenue Next Year-83.33%
Revenue Next 2Y35.4%
Revenue Next 3Y108.01%
Revenue Next 5Y96.98%
EBIT growth 1Y-0.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.85%
EBIT Next 3Y23.24%
EBIT Next 5YN/A
FCF growth 1Y7.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.95%
OCF growth 3YN/A
OCF growth 5YN/A

MOLECULAR PARTNERS AG -ADR / MOLN FAQ

What is the ChartMill fundamental rating of MOLECULAR PARTNERS AG -ADR (MOLN) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MOLN.


What is the valuation status for MOLN stock?

ChartMill assigns a valuation rating of 0 / 10 to MOLECULAR PARTNERS AG -ADR (MOLN). This can be considered as Overvalued.


Can you provide the profitability details for MOLECULAR PARTNERS AG -ADR?

MOLECULAR PARTNERS AG -ADR (MOLN) has a profitability rating of 2 / 10.


What is the financial health of MOLECULAR PARTNERS AG -ADR (MOLN) stock?

The financial health rating of MOLECULAR PARTNERS AG -ADR (MOLN) is 4 / 10.


Can you provide the expected EPS growth for MOLN stock?

The Earnings per Share (EPS) of MOLECULAR PARTNERS AG -ADR (MOLN) is expected to grow by 6.91% in the next year.